Generics in India industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2019-24, and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
- The Indian generics market recorded revenues of $36.6 billion in 2024, representing a compound annual growth rate (CAGR) of 7.0% between 2019 and 2024.
- Market consumption volume increased with a CAGR of 0.2% between 2019 and 2024, reaching a total of 99.0% of total pharma volume in 2024.
- In 2024, the revenue of the Indian generics market experienced an annual growth of 7.3%. The market’s growth is driven by the country’s aging population. According to the US Census Bureau, in 2024, the population aged 65 years and above in India reached 99.1 million, up 1.2% from 2023.
Report Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in India
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in India
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the India generics market with five year forecasts by both value and volume
Reasons to Buy
- What was the size of the India generics market by value in 2024?
- What will be the size of the India generics market in 2029?
- What factors are affecting the strength of competition in the India generics market?
- How has the market performed over the last five years?
- What are the main segments that make up India's generics market?
Table of Contents
1 Executive Summary
2 Market Overview
3 Market Data
4 Market Segmentation
5 Market Outlook
6 Five Forces Analysis
7 Competitive Landscape
8 Company Profiles
9 Macroeconomic Indicators
10 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sun Pharmaceutical Industries Ltd
- Cipla Ltd
- Lupin Ltd
- Aurobindo Pharma Ltd
- Dr. Reddy's Laboratories Ltd
